Iktos partners with Pfizer for AI-based drug design project
Category: #health  By Pankaj Singh  Date: 2021-03-03
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Iktos partners with Pfizer for AI-based drug design project
  • The company has designed the new technology for Pfizer’s small molecule discovery programs using Artificial Intelligence
  • The technology explores the chemical space by generating in silico compounds through program endpoint constraints

Iktos, an AI-based chemical research solution provider, has reportedly partnered with Pfizer in creating a design model for the pharma giants’ selective small molecule discovery programs. Generating compounds in silico within the confinements of program endpoints is one of the key aspects of this technology that helps in exploring the chemical space.

Charlotte Allerton, Pfizer’s Head of Medicine Design, has apparently expressed that the company has an active interest in Artificial Intelligence for de novo designs and that they are delighted to work with the AI startup in integrating their technology with many of Pfizer’s small-molecule programs.

Yann Gaston- Mathé, the CEO and Co-founder of Iktos, has reportedly stated that the company is delighted to work with the pharma giant and its scientists using Iktos’ software in their drug discovery programs. He further added that the AI startup aims at providing their technology to drug discovery scientists, who have an extensive understanding and knowledge of the discovery programs.

Iktos released their new generative AI-driven design software, MakyaTM for Multi-Parametric Optimization earlier this year, which is available either as a Virtual Private Cloud for customers or as a SaaS platform. The user-friendly interface of Makya allows it to be utilized by computational or medicinal chemists. It can also be used as a Python package via a Jupyter notebook interface.

With the combination of Iktos’ data science, algorithms and experience from collaborations and Pfizer’s expertise in drug discovery, Gaston- Mathé said, the AI technology promises at drastically improving the drug discovery scenario and will have a better chance of creating a substantial impact on the development of therapeutics.

For the record, Iktos is an AI startup that specializes in the development of AI-based solutions applicable to chemical research, particularly new drug design and medicinal chemistry. Incorporated in October 2016, the company is developing an innovative and proprietary solution using deep learning generative models using existing data to optimize the molecular designs in silico.

Source Credits:

https://www.businesswire.com/news/home/20210302005501/en/Iktos-Announces-Collaboration-With-Pfizer-in-AI-for-Drug-Design



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

By Pankaj Singh

La Samaritaine, a historic landmark of 19th century France, has been reportedly revamped as a new destination for dining, all-in-one shopping, and tourism by LVMH, a French luxury conglomerate. The stores&rs...

Nanjing Bioheng Biotech obtains ODD from US FDA for treating T-ALL

Nanjing Bioheng Biotech obtains ODD from US FDA for treating T-ALL

By Pankaj Singh

Bioheng Biotech Co. Ltd. has reportedly announced that its CD7-targeting T-cell therapy product, code CTD401, has obtained the Orphan Drug Designation (ODD) from the US FDA for treating T-cell acute lymphoblastic leuke...

Tiziana to initiate development of ‘Take Home’ nasal COVID treatment

Tiziana to initiate development of ‘Take Home’ nasal COVID treatment

By Pankaj Singh

Biotechnology company, Tiziana Life Sciences plc, has reportedly announced the submission of a grant to the UK-CTAP (United Kingdom COVID Therapeutics Advisory Panel).

This ...